EDIT Valuation

Editas Medicine Inc

Add to Watchlist

Advanced Chart

3.150

-0.11(-3.374%)1D

Overview
Forecast
Valuation
Earnings

EDIT Relative Valuation

EDIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EDIT is overvalued; if below, it's undervalued.

Historical Valuation

Editas Medicine Inc (EDIT) is now in the Fair zone, suggesting that its current forward PS ratio of 21.21 is considered Fairly compared with the five-year average of -6.11. The fair price of Editas Medicine Inc (EDIT) is between 0.21 to 15.63 according to relative valuation methord.

Relative Value

Fair Zone

0.21-15.63

Current Price：3.15

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

4.22

P/B

Median3y

1.71

Median5y

2.88

-78.88

FCF Yield

Median3y

-57.94

Median5y

-38.11

Competitors Valuation Multiple

The average P/S ratio for EDIT's competitors is 5.88, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT) exhibits a P/S ratio of 21.21, which is 260.46% above the industry average. Given its robust revenue growth of 310.40%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap